Summary of Product Characteristics
last updated on the eMC:
30/03/2012
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 30/03/2012 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 4.4 - Special warnings and precautions for Use
-
Change to section 10 date of revision of the text
|
| Date of revision of text on the SPC: 15-Mar-2012 |
| Legal Category: GSL |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
|
Section 4.4
Under sub heading “Stopping smoking”: olanzapine changed to olanzaprine and clozapine changed to clozaprine.
Under new sub heading “ Special warnings about excipients” additional information added:
This medicine contains low dose of extractum glycyrrhizae (liquorice) as a flavour. High and prolonged intake of liquorice may lead to mineralocorticoid effects (pseudoaldosteronism) in the form of electrolyte imbalance (sodium retention and potassium loss) accompanied by hypertension, oedema and suppression of the renin-angiotensin-aldosterone system.
However, individual tolerance varies widely and regular intake of even low amount of liquorice may cause pseudoaldosteronism in the most sensitive individuals (liquorice susceptible individuals). The possible mineralocorticoid effects due to liquorice have to be taken into consideration in liquorice susceptible patients with cardiovascular diseases and hypertension. Where use of nicotine replacement therapy is recommended the use of other flavoured nicotine medicated chewing-gums (e.g. fruit, mint or classic) may be considered.
Section 10
Change of date from 14 November 2008 to 16 March 2012
|
|
Updated on 16/12/2008 and displayed until 30/03/2012
|
Reasons for adding or updating:
|
-
New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
|
| Date of revision of text on the SPC: |
| Legal Category: GSL |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| None provided |
|